EP-100: Phase II data

The open-label, U.S. Phase II ESP2011-002 trial in 44 evaluable patients with advanced ovarian cancer showed that IV EP-100 plus paclitaxel led to an ORR, the primary endpoint, of 34.8% vs. 33.3% for ...